1130 related articles for article (PubMed ID: 29439259)
1. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
2. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
4. NKD1 correlates with a poor prognosis and inhibits cell proliferation by inducing p53 expression in hepatocellular carcinoma.
Zhang S; Li J; Wang X
Tumour Biol; 2016 Oct; 37(10):14059-14067. PubMed ID: 27507614
[TBL] [Abstract][Full Text] [Related]
5. SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein-Dependent Apoptotic Pathway.
Ran LK; Chen Y; Zhang ZZ; Tao NN; Ren JH; Zhou L; Tang H; Chen X; Chen K; Li WY; Huang AL; Chen J
Clin Cancer Res; 2016 Jul; 22(13):3372-82. PubMed ID: 26861461
[TBL] [Abstract][Full Text] [Related]
6. HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma.
Huang JL; Ren TY; Cao SW; Zheng SH; Hu XM; Hu YW; Lin L; Chen J; Zheng L; Wang Q
Oncotarget; 2015 Oct; 6(32):33791-804. PubMed ID: 26393879
[TBL] [Abstract][Full Text] [Related]
7. Pseudogene PDIA3P1 promotes cell proliferation, migration and invasion, and suppresses apoptosis in hepatocellular carcinoma by regulating the p53 pathway.
Kong Y; Zhang L; Huang Y; He T; Zhang L; Zhao X; Zhou X; Zhou D; Yan Y; Zhou J; Xie H; Zhou L; Zheng S; Wang W
Cancer Lett; 2017 Oct; 407():76-83. PubMed ID: 28823960
[TBL] [Abstract][Full Text] [Related]
8. Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Hao PP; Li H; Lee MJ; Wang YP; Kim JH; Yu GR; Lee SY; Leem SH; Jang KY; Kim DG
J Hepatol; 2015 Jun; 62(6):1278-86. PubMed ID: 25617504
[TBL] [Abstract][Full Text] [Related]
9. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways.
Chen SL; Liu LL; Wang CH; Lu SX; Yang X; He YF; Zhang CZ; Yun JP
Mol Oncol; 2020 Feb; 14(2):373-386. PubMed ID: 31670863
[TBL] [Abstract][Full Text] [Related]
10. FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo.
Fang F; Yang L; Tao Y; Qin W
Cancer; 2012 Jan; 118(1):134-46. PubMed ID: 21713761
[TBL] [Abstract][Full Text] [Related]
11. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
12. Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway.
Zhu L; Dai L; Yang N; Liu M; Ma S; Li C; Shen J; Lin T; Wang D; Pan W; Li X
Cell Biochem Funct; 2020 Jul; 38(5):621-629. PubMed ID: 32153043
[TBL] [Abstract][Full Text] [Related]
13. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway.
Liu H; Wang X; Feng B; Tang L; Li W; Zheng X; Liu Y; Peng Y; Zheng G; He Q
BMC Cancer; 2018 Jun; 18(1):661. PubMed ID: 29914442
[TBL] [Abstract][Full Text] [Related]
14. Upregulated TRIM11 Exerts its Oncogenic Effects in Hepatocellular Carcinoma Through Inhibition of P53.
Liu J; Rao J; Lou X; Zhai J; Ni Z; Wang X
Cell Physiol Biochem; 2017; 44(1):255-266. PubMed ID: 29190611
[TBL] [Abstract][Full Text] [Related]
15. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
[TBL] [Abstract][Full Text] [Related]
16. Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.
Wei S; Xiong M; Zhan DQ; Liang BY; Wang YY; Gutmann DH; Huang ZY; Chen XP
Carcinogenesis; 2012 Mar; 33(3):538-47. PubMed ID: 22226916
[TBL] [Abstract][Full Text] [Related]
17. Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma.
Jing Z; Nan KJ; Hu ML
World J Gastroenterol; 2005 Apr; 11(13):1910-6. PubMed ID: 15800979
[TBL] [Abstract][Full Text] [Related]
18. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
[TBL] [Abstract][Full Text] [Related]
19. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of Nedd4L predicts poor prognosis, promotes tumor growth and inhibits MAPK/ERK signal pathway in hepatocellular carcinoma.
Zhao F; Gong X; Liu A; Lv X; Hu B; Zhang H
Biochem Biophys Res Commun; 2018 Jan; 495(1):1136-1143. PubMed ID: 29175326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
